V. Moyo

A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.

C.S. Denlinger, M. Beeram, A. W. Tolcher et al. · Journal of Clinical Oncology · 2010 · 19 citations

Medicine, Oncology, Pharmacology +16

A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers

Gavin MacBeath, B. Adiwijaya, J. Liu et al. · Annals of Oncology · 2014 · 16 citations · Full text

Medicine, Oncology, Breast Oncology +10

A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.

M. J. Higgins, N. Gabrail, K. Miller et al. · Journal of Clinical Oncology · 2011 · 16 citations

Life Sciences, Medicinal Chemistry, Pharmacology +16

PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients

Bart S. Hendriks, Anthony F. Shields, Barry A. Siegel et al. · Annals of Oncology · 2014 · 10 citations · Full text

Medicine, Nuclear Medicine, Oncology +16